Alternate Name:Estrace
Description:Yuvafem is a prescription medicine prescribed for the treatment of vaginal symptoms of menopause. Estradiol topical is the generic version of Yuvafem. The estimated price of Yuvafem is approximately $144 for a supply of 8, 10 mcg vaginal tablets. Use our LowerMyRx savings offer to get an average Yuvafem discount of up to 80% at participating pharmacies near you.
Dosage Form:Box
Administration Route:Into the vagina
Drug Class:Endocrine-Metabolic Agent, Female Reproductive Agent
Generic Available:Yes
Strength:10 MCG
Warnings:Pregnancy after menopause is not likely, but if you think you could be pregnant, tell your doctor. This medicine could harm an unborn baby. Tell your doctor if you are breastfeeding, or if you have kidney disease, asthma, diabetes, edema, endometriosis, epilepsy, migraine headaches, porphyria, lupus, thyroid problems, heart disease, high blood pressure, high cholesterol, hereditary angioedema, bone problems, or a history of cancer. Tell your doctor if you had liver problems caused by pregnancy or estrogen. Tell your doctor if you have any problems with your vagina or in your pelvic area, including prolapse. Tell your doctor if you are having a surgery that requires inactivity for a long time. This medicine may cause the following problems: Increased risk of heart attack, stroke, or blood clotsIncreased risk of endometrial, breast, ovarian, or uterine cancerPossible risk of dementia (especially in women 65 years of age or older)Gallbladder diseaseEye or vision problemsHigh blood pressureHigh cholesterol or fats in the blood Tell any doctor or dentist who treats you that you are using this medicine. This medicine may affect certain medical test results. Your doctor will check your progress and the effects of this medicine at regular visits. Keep all appointments. Keep all medicine out of the reach of children. Never share your medicine with anyone. Sudden and severe stomach pain, nausea, vomiting Swelling in your hands, ankles, or feet Unusual vaginal bleeding, spotting, discharge, or itching Vision changes
Food Warnings:Some medicines can affect how estradiol works. Tell your doctor if you are using carbamazepine, clarithromycin, erythromycin, itraconazole, ketoconazole, phenobarbital, rifampin, ritonavir, St John's wort, or thyroid medicines., Do not eat grapefruit or drink grapefruit juice while you are using this medicine., Ask your doctor before you use other products or medicines in your vagina. You may need to remove the ring first., Tell any doctor or dentist who treats you that you are using this medicine. You may need to stop using this medicine before surgery or if you need to be on bed rest., Your doctor will check your progress and the effects of this medicine at regular visits. Keep all appointments., Keep all medicine out of the reach of children.
Read the for complete list of warnings, side effects, and other information. Do not use Estradiol topical without the authorization of your doctor. Do not use it in children under 12 years of age., Keep all your medicine out of the reach of children.Estradiol topical is not approved for use in children under 12 years of age., Keep all your medicine out of the reach of children.For more information, see.do Checkout our website have Real Patients information, click on the word "plus." If you are not sure, see, check, check, or break those checks out.For more information, see.do Checkout our website have Real Patients information, click on "plus." If you are not sure,, see, check, check, or break those.For more information, see.do Checkout our website have Real Patients information, click on "plus." If you are not sure, find the answer you needs.Estradiol is a crucial hormone produced by the ovaries during menopause, helping to manage and alleviate hormonal changes that are common during this time. This medication, like other medications used to treat estrogen-related conditions, may have a different side effect profile when used in combination with a balanced diet and regular exercise.However, it's important to note that Estradiol is not a substitute for consultation with a healthcare provider.
The global market for Estradiol, which includes hormone-positive and hormone-deficiency anemia-related conditions, is influenced by several key factors, including the rising prevalence of estrogen-related disorders and the aging population.Several factors are driving the growth of this segment.
Aromasin is a therapy approved for treatment of moderate to severe aromatase inhibitor- (A1C-) related disorders, including androgenetic alopecia (Alpernia). This medication works by reducing the levels of androgens (including estrogen) in the body.
The Estradiol market for the Estradiol drug, which is marketed under the brand name Estratest, is expected to grow significantly over the next decade or so.
The Estradiol market is dominated by several key players, including:
Key players include:
Objective:To compare the efficacy and safety of conjugated estrogens (CE) and a conjugated estradiol and estradiol and progesterone form of oral conjugates for the treatment of vaginal atrophy (VRAE) in women with idiopathic vaginal atrophy. Methods: A total of 1253 women with VRAE, age 43.5 years (n=336), and with VRAE had been treated with conjugated estrogens and conjugated estradiol and estradiol and progesterone forms of oral conjugates in combination with a progestogen for 12 months. Patients were randomized to treatment with the combined oral estrogens (CE) or a conjugated estradiol and estradiol and progesterone form of oral conjugates for 12 months. The primary end point was change in the vaginal and vulvar domains, frequency of adverse events, and number of adverse events in the postmenopausal women. The mean change from baseline in frequency of adverse events in the CE group was -3.0, -5.3, and -8.0 (P =0.049), -2.1, -0.4, -0.5, -0.8, and -4.5 (P =0.023), -0.5, -0.6, -0.6, -0.8, and -4.2 (P =0.014), -0.9, -0.3, -0.3, -0.3, and -4.5 (P =0.0004) respectively. The mean change in frequency of adverse events in the conjugated estradiol and progesterone form of oral conjugates was -2.4, -4.5, and -3.1 (P =0.0005), -1.8, -0.4, -0.6, -0.7, and -2.3 (P =0.0004), -1.4, -0.4, -0.6, -0.8, and -2.2 (P =0.0004), -1.5, -0.4, -0.6, -0.8, and -2.6 (P =0.0004), -0.7, -0.6, -0.6, and -0.7 (P =0.0004), -0.9, -0.3, -0.3, -0.5, and -4.2 (P =0.0004), -0.8, -0.3, -0.3, -0.4, and -4.5 (P =0.0004), -0.9, -0.3, -0.3, -0.5, and -4.5 (P =0.0004), -0.9, -0.3, -0.4, and -4.5 (P =0.0004), -0.9, -0.3, -0.3, -0.4, -0.6, and -4.5 (P =0.0004), and -0.9, -0.3, -0.3, -0.4, -0.6, and -0.7 (P =0.0004), and -0.9, -0.3, -0.3, -0.4, -0.6, and -0.7 (P =0.0004), respectively. No statistically significant difference was found between the efficacy and safety of estradiol and progesterone form of conjugated estradiol and estradiol and progesterone form of conjugates in women with VRAE.
Table 1. Effect of treatment with conjugated estrogens (CE) and a conjugated estradiol and estradiol and progesterone form of oral conjugates for the treatment of vaginal atrophy with postmenopausal women with idiopathic vaginal atrophy. VRAE was defined as the difference in frequency of adverse events between the CE and the conjugated estradiol and estradiol and progesterone form of oral conjugates. The mean change in frequency of adverse events in the CE group was -3.0, -5.3, and -8.0 (P =0.049), -2.1, -0.4, -0.5, -0.8, and -4.5 (P =0.023), -0.5, -0.6, -0.6, -0.8, and -2.3 (P =0.0004), -1.This report is a systematic literature review of clinical experience for women using hormone therapy and estrogen replacement therapy at the end of two years, comparing these two groups to a comparison group for two years of treatment.
The search was conducted using the Pubmed, Embase, and Cochrane Library databases using the following terms: “hormonal therapy,” “estrogen,” “estradiol,” “estradiol/estrogen receptor,” “hormone therapy,” “estrogen,” “estrogen/estrogen receptor,” “hormone therapy,” “estrogen/estrogen receptor,” “hormone therapy,” “estradiol,” “estradiol/estrogen receptor,” “hormone therapy,” “hormone therapy,” “estradiol,” “estradiol/estradiol receptor,” “hormone therapy,” “estradiol/estradiol receptor,” “estradiol/estradiol,” “estradiol,” “estradiol/estradiol,” “estradiol/estradiol,” “estradiol/estradiol,” “estradiol,” “estradiol/estradiol,” “estradiol/estradiol,” “estradiol/estradiol,” and “estradiol/estradiol).”
The study included women with a history of estrogen-related diseases, such as breast cancer, breast cancer, hormone therapy, and/or estrogen therapy. Women who were taking estrogen at the end of two years and were not able to use estrogen replacement therapy were excluded.
The study was published in June 2018 in theBritish Medical Journaland was conducted at the University of Texas Health Science Center at Houston. The study design was retrospective. The inclusion criteria included women who were included in the study and who were aged between 18 and 55 years, who were taking estrogen at the end of two years and were not able to use estrogen replacement therapy. Women who had a history of endometrial hyperplasia, uterine or uterine cancer, or uterine adenomyosis or polycystic ovary syndrome were excluded from the study.
The inclusion criteria were: women who had a history of endometrial hyperplasia, uterine or uterine cancer, or uterine adenomyosis or polycystic ovary syndrome were included.
The exclusion criteria included women who had a history of endometrial hyperplasia, uterine or uterine cancer, or uterine adenomyosis or polycystic ovary syndrome were excluded.
The full protocol and consent form were obtained from the study participants.
The study data was entered into a Microsoft Excel® file and the following information was extracted: study name, study date, study duration, patient characteristics, and study outcome. The following information was extracted from each data collection entry: study number, author, year of publication, study setting, intervention, and control arm.
The primary outcome measure was the incidence of abnormal endometrial bleeding, endometrial cancer, or endometrial hyperplasia. This outcome was assessed in a cohort of women using the American College of Obstetrics and Gynecology (ACOG) and/or American Uterine Hypertension Association (AUHA) guidelines for endometrial hyperplasia.
The secondary outcomes included the primary endpoint, the incidence of endometrial hyperplasia or endometrial cancer, endometrial-related bleeding, and endometrial-related intrauterine growth restriction (IUGR). The data were also included in the secondary outcome measures to investigate the relative risk of endometrial hyperplasia or endometrial cancer in the two groups.
Stade de France Pharmacy